Hot Growth Special Report 2006 >



Gen-Probe (GPRO)

Since its founding in 1985, Gen-Probe has quietly grown into one of the leading players in the rapidly growing market for diagnostic tools. Its vast product line includes Gen-Probe GASDirect to detect strep throat, Amplified MTD to test for tuberculosis, and Procleix, which biotech company Chiron markets to screen blood for the HIV and HCV viruses. On May 2, the San Diego company announced that its first-quarter sales grew 25% to $86.3 million and profits jumped 27% to $17.5 million. It's the continuation of a strong three-year run, during which the company's profits grew an average 62.6% annually on sales growth of 25.8% a year. Gen-Probe has a number of diagnostic products in its pipeline, including a version of Procleix that will detect West Nile virus.

Company Info

2005 Rank


Market Value*
($ Millions)


($ Millions)


Sales Growth
(3-yr. avg. annual)

25.8 %

($ Millions)


Profit Growth
(3-yr. avg. annual)

62.6 %

Return on Inv. Capital (3-yr.)

13.5 %

Share Price
12-Mo. Hi/Lo


Share Price
As of 4/28/06


Return on Equity

12.7 %

P/E Ratio


No. of Employees


Industry Health Care Supplies


Location San Diego
Phone 858 410-8000
*Trailing 12 months
Stock price data as of 4/28/06
DATA: Standard & Poor's Compustat

Related Articles

AIG Announces Management Moves

JP Morgan Upgrades Gen-Probe

Company Snapshot

Gen-Probe engages in the development, manufacture, and marketing of nucleic acid probe-based products. It products are used for clinical diagnosis of human diseases, screening of donated human blood, detection of harmful organisms in the environment, and in industrial processes. The company markets a portfolio of products that use company's technologies to detect various infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia, and fungal infections. Gen-Probe also offers blood-screening assays for the simultaneous detection of human immunodeficiency virus (type 1), hepatitis C virus, and hepatitis B virus presence. In addition, it offers TIGRIS instrument that is used for investigational use in blood screening applications in the U.S. The company markets its products to various customers, such as reference laboratories, public health laboratories, and hospitals in North America, Europe, and Japan. It has strategic alliance agreements with Chiron and Bayer. Gen-Probe was co-founded by David E. Kohne, Thomas H. Adams, and Howard C. Birndorf in 1983. The company is headquartered in San Diego.

Data provided by Capital IQ
Henry L. Nordhoff

Henry L. Nordhoff, 64

Chairman, Chief Executive Officer and President

Total Compensation*

$ 1,941,796

Total Options Value*

$ 23,155,805

* Fiscal Year 2005

Columbia University NYC?(MBA),?Johns Hopkins University?(BA in International Relations)

Executive Bio

Henry Nordhoff has been CEO and president since joining Gen-Probe in July, 1994. Prior to that, Nordhoff served as a president and CEO of TargeTech, a gene therapy company that was merged into the Immune Response. He spent most of his career at Pfizer, in senior positions in Brussels, Seoul, Tokyo, and New York. Nordhoff has been a chairman of Gen-Probe since September, 2002, and its director since July, 1994. Nordhoff has been a director of Mannkind since March, 2005, and serves as a member of the compensation committee. He received a BA in international relations and political economy from Johns Hopkins University and an MBA from Columbia University.

Management Team

Key Executives

Henry L. Nordhoff; Herm Rosenman; R. William Bowen; Niall M. Conway; Daniel L. Kacian; Larry T. Mimms

Board Directors

Mae C. Jemison; John W. Brown; Henry L. Nordhoff; Raymond V. Dittamore; Gerald D. Laubach; Abraham D. Sofaer; Brian A. McNamee; Armin M. Kessler; Phillip M. Schneider

Executive Data provided by Capital IQ